Apr 08, 2019
WuXi Biologics and NBE-Therapeutics Announce Comprehensive ADC Development and Manufacturing Partnership
Mar 25, 2019
WuXi Biologics Receives "Asia's Best CMO of 2018" Award from IMAPAC
Mar 19, 2019
WuXi Biologics Receives EMA GMP Certificates
Feb 27, 2019
WuXi Biologics Congratulates Amicus on Receiving FDA Breakthrough Therapy Designation for AT-GAA
Feb 25, 2019
ABL Bio Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody(TM) Platform for Novel Immune Check Point Bispecifics for $220 Million
Feb 18, 2019
EMA Completed Pre-Approval Inspection of cGMP DS and DP Facilities for Trogarzo(TM) at WuXi Biologics
Feb 11, 2019
WuXi Biologics and Amicus Sign Exclusive Manufacturing Partnership
Dec 19, 2018
WuXi Biologics and AC Immune to Establish an Exclusive Strategic Partnership
Dec 12, 2018
WuXi Biologics Congratulates Tychan on First-in-Class Monoclonal Antibody for Yellow Fever after Record 7 Months of Development
Dec 11, 2018
WuXi Biologics Achieves Breakthrough Titer of 51g/L in Cell Culture Productivity
Dec 10, 2018
Oxford BioTherapeutics Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody(TM) Platform for Five Bispecific Antibody Programs for up to $450 Million
Dec 09, 2018
WuXi Biologics Announced Exclusive Discovery Research with Brii Biosciences for Novel Bispecific Antibody Immunotherapeutics
Dec 05, 2018
WuXi Biologics Commenced Construction of the Largest Biomanufacturing Facility Using Single-Use Bioreactors in Ireland
Nov 28, 2018
WuXi Biologics and ABL Bio Enter an Exclusive Development and Clinical Manufacturing Partnership for Multiple Bispecific Antibodies
Nov 22, 2018
WuXi Biologics Commenced Construction of 1.6 million sq. ft. Biologics Innovation Center in Shanghai
Nov 07, 2018
WuXi Biologics' Chief Executive Officer Dr. Chris Chen to Serve on Board of Directors at ISPE and Delivered Keynote Speech at 2018 Annual Meeting
Oct 31, 2018
WuXi Biologics Commenced Construction of 48,000L Biologics Commercial Manufacturing Center in Shijiazhuang
Oct 23, 2018
CANbridge Pharmaceutical and WuXi Biologics Enter into Strategic Partnership for Rare Disease Therapeutics
Sep 26, 2018
I-Mab Biopharma Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody(TM) Platform for Three Bispecific Antibody Programs
Sep 24, 2018
WuXi Biologics Appoints Harvard Professor David R. Liu to Scientific Advisory Board